HOME >> BIOLOGY >> NEWS
Therapeutic cloning no longer a dream, says scientist who produced first cloned embryonic stem cell

Berlin, Germany: A member of the team who were the first in the world to produce stem cells from a cloned human embryo told the 20th annual conference of the European Society for Human Reproduction and Embryology today (30 June) that the work could generate potentially unlimited undifferentiated stem cells. These could eventually be used for tissue repair and transplantation medicine, said Professor Shin-Yong Moon at a media briefing.

Professor Moon and his colleagues at Seoul National University, South Korea, took 242 eggs from 16 healthy donors. Using the cloning technique somatic cell nuclear transfer (SNCT), the researchers removed the nucleus of each unfertilised egg and replacing it with the nucleus taken from a cell from the cumulus the clump of cells that surrounds the egg - of the donor. The eggs were then stimulated to begin dividing and after a few days 30 blastocysts were produced. From these the researchers were able to extract one colony of stem cells.

Although the procedure is highly experimental and still needs refinement, its publication was greeted with great enthusiasm because of its potential to produce stem cells which are genetically identical to the donor. In principle stem cells can be directed to develop into any tissue.

"This means that patients who received them as part of a treatment would not reject the cells as foreign", said Professor Moon. "We call this therapeutic cloning to differentiate it from reproductive cloning, where the aim would be to implant the cloned embryo into a woman in order to produce a baby. In therapeutic cloning, the embryo is destroyed after the stem cells have been harvested."

Scientists believe that therapeutic cloning holds great promise for the treatment of a large number of currently untreatable conditions, including many inherited diseases.

"Our first attempt was clearly not very efficient",
'"/>

Contact: Mary Rice
mary.rice@blueprintpartners.be
European Society for Human Reproduction and Embryology
30-Jun-2004


Page: 1 2

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Therapeutic cloning may be permitted at Newcastle University
4. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
5. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
6. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
7. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
8. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
9. Immerge BioTherapeutics announces identification of PERV receptor
10. Hemocellular Therapeutics establishes licensing agreement with UNC, ECU
11. Dana-Farber launches NFCR Center for Therapeutic Antibody Research and Engineering

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/30/2019)... ... September 30, 2019 , ... ... organization focused on molecular manufacturing and other transformative technologies, announced the 2018 ... College graduate or undergraduate student whose work is considered most notable in ...
(Date:9/24/2019)... ... September 23, 2019 , ... ... Cambridge, MA, announce today that Holotype HLA and other Omixon products will be ... the American Society for Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, PA. ...
(Date:9/17/2019)... ... 17, 2019 , ... VISTAAR released ADVISORY Playbooks to help small ... / 2nd opinion to their internal strategies they formed for developing or launching new ... new markets, or planning to change their product elements and want to know the ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... ... October 10, 2019 , ... VirTrial today ... centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable ... certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT). ...
(Date:10/8/2019)... ... ... Today, Massachusetts stem cell biotechnology company Asymmetrex announces the recent patenting in ... in the U.S. in 2017, the new patent covers the company’s unique technology for ... in the U.S. as the AlphaSTEM Test™. The new patent will support marketing ...
(Date:10/3/2019)... ... 2019 , ... Today marked the official launch of ... outsourcing success by cultivating radical improvements in leadership, staff, and broader project team ... phaseUP™ brings clients deep, broad and unique expertise in the intricacies of drug ...
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid Novor, Inc., the world's ... it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. Now home ... the company's continuous commitment to quality research and service offerings. , ...
Breaking Biology Technology:
Cached News: